Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101™ in blood cancers.

Based on positive Phase II data, Kiadis Pharma has taken the decision to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead product ATIR101™ for use in blood cancers to reduce relapse rates, Transplant Related Mortality (TRM) and Graft-versus-Host-Disease (GVHD) in the context of a hematopoietic stem cell transplantation using a haploidentical donor.

Read More

In this section you can find out more about our investor activities: company news releases, financial calendar, presentations, stock and shareholder information and latest financial reports.